(NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio ...

Tony Sycamore, Market Analyst, IG updated his views and thoughts on financial markets, including the technical analysis ...

Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Enphase Energy. If we consider the specifics of ...

EIDO offers a purer play on Indonesian equities, with financials making up nearly half its holdings. See why I rate the fund ...

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...

In a webcast with his colleagues, strategists Mathieu Savary and Matt Gertken, Papic explains that the U.S. indeed was exceptional between 2010 and 2020, thanks to a low growth, low inflation, ...

Bitcoin hovered below $85K as macro tensions and ETF outflows weighed on sentiment, while Core led altcoin gains.

Led Network Rooted in Clinical Excellence and Shared Values CHICAGO, IL / ACCESS Newswire / April 16, 2025 /Phase 1 Equity, a ...

On Wednesday, options and futures tied to the Cboe Volatility Index expired during a monthly event known on Wall Street as ...